A biochemistry student is comparing two enzyme inhibitors used in drug design. Inhibitor A increases the apparent Km while leaving Vmax unchanged. Inhibitor B decreases Vmax while leaving Km unchanged. Which kinetic feature best distinguishes competitive inhibition from non-competitive inhibition?

## Michaelis-Menten Kinetics: Competitive vs Non-Competitive Inhibition ### Key Kinetic Definitions **Key Point:** The Michaelis-Menten equation describes enzyme velocity as a function of substrate concentration: $V = \frac{V_{max} \cdot [S]}{K_m + [S]}$ Where: - $V_{max}$ = maximum velocity (enzyme saturation limit) - $K_m$ = Michaelis constant (substrate concentration at half-maximal velocity) - $[S]$ = substrate concentration ### Competitive Inhibition **High-Yield:** Competitive inhibitors bind to the **active site** and compete directly with substrate. | Feature | Effect | Mechanism | |---------|--------|----------| | **Km** | Increases (apparent) | More substrate needed to achieve same velocity | | **Vmax** | Unchanged | Inhibitor can be outcompeted at high [S] | | **Lineweaver-Burk plot** | Increased x-intercept (−1/Km), same y-intercept (1/Vmax) | | | **Reversibility** | Reversible (usually) | Competitive binding is equilibrium-based | ### Non-Competitive Inhibition **High-Yield:** Non-competitive inhibitors bind to a **site other than the active site** (allosteric or enzyme surface) and do NOT compete with substrate. | Feature | Effect | Mechanism | |---------|--------|----------| | **Km** | Unchanged | Substrate binding affinity unaffected | | **Vmax** | Decreases | Inhibitor reduces catalytic efficiency regardless of [S] | | **Lineweaver-Burk plot** | Same x-intercept (−1/Km), increased y-intercept (1/Vmax) | | | **Reversibility** | Reversible or irreversible | Depends on binding strength | ### Comparative Table: The Discriminating Features | Inhibition Type | Km | Vmax | Best Discriminator | |---|---|---|---| | **Competitive** | ↑ (apparent) | → (unchanged) | **Increased Km, normal Vmax** | | **Non-competitive** | → (unchanged) | ↓ | **Unchanged Km, decreased Vmax** | | **Uncompetitive** | ↓ | ↓ | Both decrease proportionally | **Key Point:** The **change in Km with unchanged Vmax** is the pathognomonic feature of competitive inhibition. This is because the inhibitor competes at the active site, making it appear that more substrate is needed (higher Km), but maximum velocity remains achievable if substrate concentration is raised sufficiently. ### Clinical Pearl Many clinically important drug interactions involve competitive inhibition. For example: - **Statins** competing with HMG-CoA for HMG-CoA reductase - **ACE inhibitors** competing with angiotensinogen for ACE - **Warfarin** competing with vitamin K antagonism sites In these cases, increasing substrate (or cofactor) concentration can overcome inhibition — a key therapeutic principle. ### Mnemonic **"C-Km"** = **C**ompetitive inhibition increases **Km** **"NC-Vmax"** = **N**on-**C**ompetitive inhibition decreases **Vmax** **Tip:** On Lineweaver-Burk plots (double-reciprocal plots), competitive inhibition shows lines that intersect on the y-axis (same 1/Vmax), while non-competitive inhibition shows lines that intersect on the x-axis (same −1/Km).